Phase 1 safety, tolerability, pharmacokinetics and pharmacodynamic results of KCL‐286, a novel retinoic acid receptor‐β agonist for treatment of spinal cord injury, in male healthy participants
Open Access
- 9 August 2023
- journal article
- research article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 89 (12) , 3573-3583
Abstract
Aims: KCL‐286 is an orally available agonist that activates the retinoic acid receptor (RAR) β2, a transcription factor which stimulates axonal outgrowth. The investigational medicinal product is being developed for treatment of spinal cord injury (SCI). This adaptive dose escalation study evaluated the tolerability, safety and pharmacokinetics and pharmacodynamic activity of KCL‐286 in male healthy volunteers to establish dosing to be used in the SCI patient population.Methods: The design was a double blind, randomized, placebo‐controlled dose escalation study in 2 parts: a single ascending dose adaptive design with a food interaction arm, and a multiple ascending dose design. RARβ2 mRNA expression was evaluated in white blood cells.Results: At the highest single and multiple ascending doses (100 mg), no trends or clinically important differences were noted in the incidence or intensity of adverse events (AEs), serious AEs or other safety assessments with none leading to withdrawal from the study. The AEs were dry skin, rash, skin exfoliation, raised liver enzymes and eye disorders. There was an increase in mean maximum observed concentration and area under the plasma concentration–time curve up to 24 h showing a trend to subproportionality with dose. RARβ2 was upregulated by the investigational medicinal product in white blood cells.Conclusion: KCL‐286 was well tolerated by healthy human participants following doses that exceeded potentially clinically relevant plasma exposures based on preclinical in vivo models. Target engagement shows the drug candidate activates its receptor. These findings support further development of KCL‐286 as a novel oral treatment for SCI.Keywords
Funding Information
- Medical Research Council (MR/R006466/1)
This publication has 32 references indexed in Scilit:
- Cloning and expression of a retinoic acid receptor β2 subtype from the adult newt: Evidence for an early role in tail and caudal spinal cord regenerationDevelopmental Dynamics, 2011
- RA–RAR-β counteracts myelin-dependent inhibition of neurite outgrowth via Lingo-1 repressionJournal of Cell Biology, 2011
- Drug transport in brain via the cerebrospinal fluidFluids and Barriers of the CNS, 2011
- A retinoic acid receptor β agonist (CD2019) overcomes inhibition of axonal outgrowth via phosphoinositide 3-kinase signalling in the injured adult spinal cordNeurobiology of Disease, 2010
- Repair and rehabilitation of plexus and root avulsions in animal models and patientsCurrent Opinion in Neurology, 2009
- Role of Fatty Acid Binding Proteins and Long Chain Fatty Acids in Modulating Nuclear Receptors and Gene TranscriptionLipids, 2007
- Lentiviral vector expressing retinoic acid receptor β2 promotes recovery of function after corticospinal tract injury in the adult rat spinal cordHuman Molecular Genetics, 2006
- Retinoic acid receptor β2 promotes functional regeneration of sensory axons in the spinal cordNature Neuroscience, 2005
- Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor α (RAR α ) and oncogenic RAR α fusion proteinsProceedings of the National Academy of Sciences, 1999
- Mouse and human retinoic acid receptor β2 promoters: sequence comparison and localization of retinoic acid responsivenessDNA Sequence, 1991